Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy

Table 1 Patients baseline and end of treatment charactarestics

	Gender	Age attreatment start	HCV genotype	Immune suppression	Baseline ALT U/L	Baseline RNA × 106	Time transplant to treatment (m)	Treatment regimen	End of treatment ALT U/L	End of treatment biopsy
										Treatment to biopsy (wk)	Inflammation grade	Fibrosis stage	Other findings
1	F	59	1a	MMF, tacrolimus	57	1.3	22 mo	SOF/SIM	18	25	2	1
2	M	57	1a	Tacrolimus	12	0.3	32 d	SOF/RBV	17	22	0	0	Mild centrilobular dilatation with focal hemorrhage
3	M	59	1a	MMF, tacrolimus	85	4.0	13 mo	SOF/RBV > SOF/SIM	11	32	2	0
4	M	61	1a or 1b	Tacrolimus	20	0.1	5 mo	SOF/RBV	16	22	3	0
5	M	68	1a or 1b	Tacrolimus	44	1.2	8.5 yr	SOF/RBV	18	25	1	3
6	F	76	1a	Tacrolimus	20	10.6	5.5 mo	SOF/SIM	48	25	2	0	Histocytes granuloma
7	F	80	1a	Tacrolimus	12	5.2	18 yr	SOF/SIM	15	24	3	2
8	M	62	1a	MMF, tacrolimus	166	1.7	43 d	SOF/RBV	9	30	1	0	Steatosis (< 5%)
9	M	60	3a	Tacrolimus, prednisone	23	0.9	4 mo	SOF/RBV	82	33	1	0	Rare councilmen bodies
10	M	58	1a	Tacrolimus	25	1.7	20 mo	SOF/RBV	30	25	4	3	Mild TCMR cannot be ruled out
11	M	53	3a	Cyclosporine	78	5.2	4.5 yr	SOF/RBV	37	23	4	2	Mild TCMR cannot be ruled out. Two portal tracts show non-necrotizing granulomas
12	F	61	2b	Tacrolimus	43	7.6	6 mo	SOF/RBV	34	20	2	1
13	M	65	1a	Tacrolimus	94	2.0	7.5 yr	SOF/RBV > SOF/SIM	14	29	2	2	Mild absence of bile ducts

ALT: Alanine aminotransferase; MMF: Mycophenolate mofetil; RBV: Ribavirin; SIM: Simeprevir; SOF: Sofosbuvir.

Table 2 End of treatment biopsy compared to prior to treatment biopsy

Patient number	Weeks from biopsy to treatment start	Prior to treatment inflammation grade	End of treatment
			Inflammation
			Grade	Change
1	10	1	2	↑
5	14	2	1	↓
10	22	3	4	↑
11	18	3	4	↑
13	26	2	2	↔

↑: Increased; ↔ : Unchanged; ↓: Improved.

Table 3 End of treatment biopsy compared to follow up biopsy

Patient number	End of treatment biopsy		Weeks between both biopsies	ALT	Follow up biopsy
	Inflammation	Fibrosis			Inflammation	Fibrosis
3	2	0	38	20	1 ↓	0 ↔
4	3	0	42	15	2 ↓	1 ↑
5	1	3	43	20	2 ↑	3 ↔
10	4	3	48	22	2 ↓	3↔
11	4	2	44	71	3 ↓	3 ↑

↑: Increased; ↔ : Unchanged; ↓: Improved.

ALT: Alanine aminotransferase.